A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia

BACKGROUND: Cancer cachexia is characterized by weight loss and is associated with increased morbidity and mortality in patients with cancer. Anamorelin (ONO‐7643; ANAM) is a novel and selective ghrelin receptor agonist that improves appetite, lean body mass (LBM), body weight, and anorexia. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamauchi, Satoshi, Furuse, Junji, Takano, Toshimi, Munemoto, Yoshinori, Furuya, Ken, Baba, Hideo, Takeuchi, Manabu, Choda, Yasuhiro, Higashiguchi, Takashi, Naito, Tateaki, Muro, Kei, Takayama, Koichi, Oyama, Shusuke, Takiguchi, Toru, Komura, Naoyuki, Tamura, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900019/
https://www.ncbi.nlm.nih.gov/pubmed/31415709
http://dx.doi.org/10.1002/cncr.32406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900019/
https://www.ncbi.nlm.nih.gov/pubmed/31415709
http://dx.doi.org/10.1002/cncr.32406

Ejemplares similares